^
    Back
    Association details:
    Biomarker:EGFR mutation + RBBP8 underexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JTO Clin Res Rep
    Title:

    BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

    Published date:
    10/23/2020
    Excerpt:
    ...in the CtIP-low group, median PFS was numerically longer with gefitinib plus olaparib (12.5 mo, 95% CI: 5.4–not reached) compared with gefitinib alone (9.2 mo, 95% CI: 6.6–10.2) (p = 0.2479)….In this study,we observed that low CtIP mRNA levels predicted longer PFS in EGFR-mutant patients treated with gefitinib plus olaparib, in comparison with those treated with gefitinib single agent.
    DOI:
    10.1016/j.jtocrr.2020.100113
    Trial ID:
    GOAL